Oncolytics Biotech’s (ONCY) “Buy” Rating Reiterated at HC Wainwright

HC Wainwright restated their buy rating on shares of Oncolytics Biotech (NASDAQ:ONCY) in a report released on Wednesday morning, Benzinga reports. HC Wainwright currently has a $5.00 target price on the stock. HC Wainwright also issued estimates for Oncolytics Biotech’s FY2024 earnings at ($0.29) EPS.

Oncolytics Biotech Stock Up 4.2 %

Shares of NASDAQ:ONCY opened at $0.99 on Wednesday. Oncolytics Biotech has a 52-week low of $0.85 and a 52-week high of $2.49. The stock has a market cap of $76.09 million, a price-to-earnings ratio of -3.30 and a beta of 1.91. The business has a 50-day moving average price of $1.01 and a 200-day moving average price of $1.05.

Oncolytics Biotech (NASDAQ:ONCY) last posted its earnings results on Thursday, August 1st. The company reported ($0.07) EPS for the quarter, topping the consensus estimate of ($0.08) by $0.01. During the same period last year, the business earned ($0.09) EPS. As a group, equities analysts anticipate that Oncolytics Biotech will post -0.29 EPS for the current fiscal year.

Institutional Trading of Oncolytics Biotech

A hedge fund recently bought a new stake in Oncolytics Biotech stock. Virtu Financial LLC bought a new position in shares of Oncolytics Biotech Inc. (NASDAQ:ONCY) during the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm bought 51,889 shares of the company’s stock, valued at approximately $55,000. Virtu Financial LLC owned 0.07% of Oncolytics Biotech as of its most recent SEC filing. Institutional investors and hedge funds own 6.82% of the company’s stock.

About Oncolytics Biotech

Oncolytics Biotech Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma.